Financière de Tubize
Financière de Tubize is an investment holding company that primarily operates within the biopharmaceuticals sector. It holds a significant stake in UCB, a global biotechnology firm renowned for developing treatments for neurological and immunological conditions. UCB generates most of its revenue from the United States, with additional sales in Europe and other international markets. The company's product lineup predominantly features neurology-related therapies, followed by immunology treatments. UCB's strategic approach emphasizes the application of scientific advancements and expertise in genetics, biomarkers, and human biology to drive innovation and growth in its market offerings.
UCB SA, established in 1928, is a Belgium-based biopharmaceutical company that develops and markets therapies for neurology and immunology diseases. Its primary products include Cimzia for inflammatory diseases, Vimpat and Briviact for epilepsy, Neupro for Parkinson's disease and restless legs syndrome, and Nayzilam for seizure clusters. Additionally, UCB offers treatments for allergies, memory problems, narcolepsy, and osteoporosis. The company is also involved in developing novel therapies for conditions like myasthenia gravis, drug-resistant epilepsy, and systemic lupus erythematosus. UCB engages in research and development activities in neurology, immunology, and other areas, and has collaboration agreements with several pharmaceutical companies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.